Authors
Latest:
Similarity of Biosimilars and BiologicsThomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.
Latest:
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of RelapseThomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.
Latest:
Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic CancersThomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.
Latest:
Dr. Hope on the Impact of Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate CancerThomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.
Latest:
Dr. Lynch on Targeting EGFR Mutation Subtypes in Lung CancerThomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.
Latest:
Precision Medicine: A Promising Future for Treating CancerThomas J. Lynch, MD, director, Yale Cancer Center, Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven, writes about precision medicine in oncology.
Latest:
Dr. Polascik on Harmonizing Genetic Testing Guidelines in Prostate CancerThomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.
Latest:
Dr. Semrad on SPIDER Program to Understand Resistance to TherapiesThomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.
Latest:
Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular CarcinomaSeveral breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.
Latest:
Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic MalignanciesThomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.
Latest:
Dr. Lynch on the Goals of Bristol-Myers SquibbThomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses goals at Bristol-Myers Squibb.
Latest:
Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCCThomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.
Latest:
Cancer Hijacks Your Bone Marrow and Your Immune System: What Are You Going to Do About It?Thomas Marron, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses the ways cancer attacks the bone marrow and immune system.
Latest:
Single-Agent Immune Therapy in UC: The Need for MoreThomas Powles, MBBS, MRCP, MD, discusses how different trials have been used to study urothelial cancer (UC) treatments, including DANUBE, IMvigor130, and KEYNOTE-361, all of which are frontline, randomized, phase 3 studies that were unsuccessful. A trial that had better results involved nivolumab plus gemcitabine/cisplatin, due to patients being in better physical condition to withstand chemotherapy.
Latest:
Dr Powles on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial CancerThomas Powles, MD, MBBS, MRCP, discusses the use of enfortumab vedotin plus pembrolizumab in urothelial carcinoma based on data from the KEYNOTE-A39 trial.
Latest:
Understanding Unprecedented Data in Genitourinary Cancers From ESMO 2023: Dr PowlesOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
